Q&A with the Portfolio Manager: Global Healthcare Equities

1. Although COVID-19 is largely behind us, market concerns about a looming economic recession linger. Can you illustrate the defensiveness of this sector and its sub-sectors during previous market downturns? 

As the Macroeconomic Strategy Team highlighted in its Global Macro Outlook Q3 2023, the recession has been postponed, not cancelled. Market concerns about a U.S. economic recession will likely be carried over to the second half of this year.

As our investors know, the healthcare sector remains one of the most recession-resistant areas of the economy. It has been a defensive stalwart during enhanced volatility and economic uncertainty. In particular, the outperformance of healthcare in recent economic downturns was primarily due to inelastic demand for medical resources.

During the most recent recessionary periods, sub-sector dispersion was wide. Pharmaceuticals generally provided good, sometimes better, protection, while biotech outperformed in three out of the recent four market downturns. Also, healthcare providers & services witnessed increased returns in the last three recessions. (Refer to Chart 1).

2. What has differentiated our healthcare investment capabilities throughout market ups and downs? 

The proprietary fundamental research conducted on a daily basis by seasoned investment professionals with solid medical backgrounds underpins our differentiated investment approach. On average, our portfolio managers have over 30 years of experience spanning large-scale multinational healthcare corporations to global asset management firms. This has laid a solid foundation that helps us make vital investment considerations across the broader healthcare landscape. Slaughter’s educational background in biology, as well as Sylvester’s in biology, neurobiology, and physiology, empower our team with the knowledge base to effectively engage with the medical and scientific communities on the cutting-edge technologies and advancements within healthcare. This, combined with deep industry expertise required for dedicated fundamental research enable us to uncover compelling investment ideas before they are fully appreciated by a broader cohort of market participants.

Adding a layer of scientific research based on fundamental equity analysis

Besides traditional fundamental equity analysis via investment screens and financial modelling, our team devotes energy and passion to building an in-depth and insightful scientific understanding of the healthcare sector. This is based on proprietary fundamental research from: 

• Clinic and hospital visits
• Company meetings
• Investor conferences
• Medical journal reviews
• Medical conferences
• Prior holdings

During the research process, our team members act as stewards, proactively attending company meetings and investor conferences, liaising with industry thought leaders, as well as engaging with C-suites and board members (not limited to only companies owned in our portfolio). Our long-standing corporate relationships also enable our team to conduct objective environmental, social, and governance (ESG) analysis of risks and opportunities – driving the positive change that could benefit long-term, value-driven company growth.

The longevity of our on-the-ground research capabilities is instrumental in the bottom-up decision-making process. This includes: i) evaluating end-market size and product demand, ii) identifying product-pipeline strength and conducting competitor product analysis, and iii) assessing the strength of management teams.

Given our passion for the ever-changing healthcare industry, we monitor and digest medical journals and scientific publications from a practitioner’s viewpoint. This approach ensures we are aware of medical advances in pharmaceutical and therapeutic landscapes. As a result, we can avoid over-reliance on secondary or sell-side research, allowing us to independently evaluate markets, uncover hidden ideas, develop in-depth analysis, and make judgements beyond financial numbers and market sentiment. The art of marrying quantitative and qualitative inputs is our main proprietary asset for idea generation – a unique interactive research process that could unlock underappreciated market opportunities.

3. Emerging evidence of adverse health outcomes for patients previously infected with COVID increases the importance of addressing such unmet medical needs. How do you apply your proprietary research approach when identifying alpha-generation opportunities resulting from the long-term impact of the pandemic? 

As we highlighted in our 2023 outlook, Manulife IM’s fundamental research process has identified a series of published research studies noting increased morbidity among patients recovering from COVID-19 infections and, as evidenced by, an elevated risk of cardiovascular diseases, diabetes, and central nervous system (CNS) diseases relative to the uninfected population. Coupled with the unmet medical needs for pre-existing conditions, we believe that opportunities abound for experienced investors with keen insights who can identify underappreciated market opportunities and deliver outperformance. Our approach continues to inform how we evaluate investment opportunities across the healthcare universe. To this end, the findings mentioned above relating to structural changes in healthcare (including, but not limited to, long COVID) support the urgency to manage other pre-existing diseases effectively, diagnoses that our research suggests pre-dispose these comorbid patients to higher morbidity and mortality from COVID-19. For example, we continue to look at companies with novel treatments for CNS diseases (depression, Alzheimer’s) and continue to focus on orphan diseases (i.e., those affecting fewer than 200,000 individuals). We see a greater understanding of the genetic causes of these diseases, and those learnings are being applied to novel drugs that could dramatically impact patients. We are also identifying smaller biotech names with significant upside and alpha generation potential, given that these companies’ innovations are in the final phases of clinical development.

Conclusion

Overall, we believe the healthcare sector will remain one of the most defensive segments in any potential economic recession scenario. Additionally, the unprecedented innovation and medical advancements expected in a post-COVID-19 era should provide a fertile opportunity set for market beating growth. Our differentiated research approach, underpinned by experienced and seasoned investment professionals with solid medical backgrounds, allows us to look beyond financial figures and market sentiment to identify companies with potential upside and alpha generation at an earlier stage than others.

We continue to see unprecedented demand among companies with products and services that address all three guiding principles: i) unmet medical needs, ii) underappreciated market opportunities, and iii) the ability to bend the healthcare cost curve.